CRP and androgen insensitivity syndrome: In line with previous reports suggesting a multimarker approach to improve outcome prediction in AIS patients [29], our data indicate that calprotectin either alone or even better when combined with CRP and NLR could improve the overall prediction of 3-month mortality in AIS, suggesting that an elevated inflammatory state may contribute to the mortality in AIS patients.